AbbVie Inc. (ABBV)
ABBV vs. MRK: Which Drug Giant is a Better Buy Now?
Both ABBV and MRK are leading pharmaceutical companies with strong portfolios in oncology and immunology.
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis
AbbVie's, Rinvoq and AstraZeneca's and Novartis are included in this Analyst Blog.
This Pharma Giant Will Invest $23 Billion in the U.S. It's a Sign Trump's Tariffs Are Working.
The Company spend billions to produce 100% of its key medicines for Americans in the U.S.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AbbVie Stock Up 9.2% After Key Signal
ALERT COMES AT LOW POINT FOR ABBV AND SIGNALS MAJOR REVERSAL OF OVER 15 POINTS
AbbVie: Thriving Beyond Humira's Patent Cliff (Upgrade)
AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% year-over-year, projecting combined revenue exceeding $31 billion by 2027. Despite Imbruvica's 7% decline, the oncology portfolio grew 11% through Venclexta and Elahere's strong performance.
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturing, companies like Eli Lilly and Novo Nordisk are suffering substantial share price declines. The feasibility of relocating drug manufacturing to the U.S. is highly questionable, potentially leading to drug shortages and higher domestic prices.
AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis
European Commission approves ABBV's Rinvoq for its eighth indication, giant cell arteritis.
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes
Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.
3 Dividend Stocks to Buy and Hold for the Next Decade
What should investors do when stocks are tanking over the short term? Probably the best answer is to think long term.
2 Dividend Stocks to Buy Hand Over Fist in April
One factor that keeps some investors away from healthcare stocks is the sector's dearth of generous and reliable dividend payers. This stands to reason, as nearly every stage of drug development and marketing is resource- and capital-intensive, and as a result, cash can be in short supply.
3 High-Yielding Dividend Stocks That Retirees Can Buy and Forget About
"Buy and hold" is a simple strategy for investors, but it can be a hard one to stick to in actual practice. That's because many people want to pick stocks and trade them, and feel like they need to actively intervene to generate significant gains.
